Annovis Bio Partners with Pfizer for Alzheimer's Trial
Ticker: ANVS · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $9.48, $3,000,000 |
| Sentiment | mixed |
Sentiment: mixed
Topics: collaboration, clinical-trial, alzheimers, partnership
Related Tickers: PFE
TL;DR
Annovis Bio teams up with Pfizer to test their Alzheimer's drug combo!
AI Summary
Annovis Bio, Inc. announced on March 22, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the combination of Annovis' lead drug candidate, ANVS401 (posiphen), with Pfizer's investigational drug, PF-07321332 (nirmatrelvir), in patients with Alzheimer's disease. This collaboration aims to explore potential synergistic effects in treating neurodegenerative diseases.
Why It Matters
This collaboration with a major pharmaceutical company like Pfizer could significantly accelerate the development and potential approval of Annovis Bio's drug for Alzheimer's disease, offering new hope for patients.
Risk Assessment
Risk Level: medium — The success of this collaboration is dependent on the clinical trial results, which are inherently uncertain, and the partnership involves a large, established company, potentially shifting some risk but also indicating the early stage of Annovis' drug.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Pfizer Inc. (company) — Collaborator
- ANVS401 (posiphen) (drug) — Annovis Bio's lead drug candidate
- PF-07321332 (nirmatrelvir) (drug) — Pfizer's investigational drug
- Alzheimer's disease (disease) — Target indication
- March 22, 2024 (date) — Announcement date
FAQ
What is the primary goal of the clinical trial collaboration between Annovis Bio and Pfizer?
The primary goal is to evaluate the combination of Annovis' ANVS401 (posiphen) with Pfizer's PF-07321332 (nirmatrelvir) in patients with Alzheimer's disease to explore potential synergistic effects.
Which specific drugs are involved in this collaboration?
The collaboration involves Annovis Bio's ANVS401 (posiphen) and Pfizer's investigational drug PF-07321332 (nirmatrelvir).
What is the reported date of this announcement?
The report date is March 22, 2024.
What is the target disease for this clinical trial?
The target disease for this clinical trial is Alzheimer's disease.
What is the relationship between Annovis Bio and Pfizer in this filing?
Annovis Bio, Inc. has entered into a clinical trial collaboration with Pfizer Inc.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-22 17:24:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
- $9.48 — alue per share (the "Common Shares") at $9.48 per share (the "Offering"). On March 2
- $3,000,000 — Company closed the Offering and raised $3,000,000 in gross proceeds from the Offering. Th
Filing Documents
- tm249453d2_8k.htm (8-K) — 25KB
- 0001104659-24-037958.txt ( ) — 196KB
- anvs-20240322.xsd (EX-101.SCH) — 3KB
- anvs-20240322_lab.xml (EX-101.LAB) — 33KB
- anvs-20240322_pre.xml (EX-101.PRE) — 22KB
- tm249453d2_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Information. As disclosed on the Form 8-K filed with the Securities and Exchange Commission (the "Commission") on March 21, 2024, Annovis Bio, Inc. (the "Company") entered into a Securities Purchase Agreement, dated March 21, 2024 (the "Purchase Agreement") with an institutional investor (the "Buyer"), pursuant to which the Company agreed to issue and sell to the Buyer an aggregate of 316,455 shares of Common Stock, 0.0001 par value per share (the "Common Shares") at $9.48 per share (the "Offering"). On March 22, 2024, the Company closed the Offering and raised $3,000,000 in gross proceeds from the Offering. The Common Shares were issued pursuant to a currently effective shelf registration statement on Form S-3 (Registration No. 333-276814), which was filed with the United States Securities and Exchange Commission on February 1, 2024, as amended on February 12, 2024 and was declared effective on February 12, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: March 22, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer